Fiduciary Family Office LLC Takes Position in Pfizer Inc. (NYSE:PFE)

Key Points

• Fiduciary Family Office LLC has acquired 14,453 shares of Pfizer, valued at approximately $366,000, marking a significant new position in the company's stock.
• Pfizer reported a quarterly earnings per share of $0.78, surpassing analysts' expectations of $0.58, with a revenue of $14.65 billion for the quarter.
• The company announced a quarterly dividend payment of $0.43 per share, reflecting an annualized dividend yield of 7.0% with a payout ratio of 91.49%.

Fiduciary Family Office LLC purchased a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,453 shares of the biopharmaceutical company's stock, valued at approximately $366,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. William B. Walkup & Associates Inc. lifted its holdings in shares of Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company's stock valued at $1,044,000 after buying an additional 454 shares during the period. Members Trust Co raised its holdings in Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after purchasing an additional 467 shares during the period. Sutton Place Investors LLC raised its holdings in Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company's stock worth $224,000 after purchasing an additional 472 shares during the period. Bellevue Group AG raised its holdings in Pfizer by 0.3% in the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company's stock worth $3,756,000 after purchasing an additional 485 shares during the period. Finally, Gould Capital LLC raised its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 493 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Up 1.7%

PFE traded up $0.43 during mid-day trading on Wednesday, hitting $25.08. 25,834,230 shares of the stock were exchanged, compared to its average volume of 45,745,871. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The firm's fifty day moving average is $24.49 and its two-hundred day moving average is $24.47. The company has a market cap of $142.57 billion, a PE ratio of 13.33, a PEG ratio of 0.88 and a beta of 0.52. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.60 earnings per share. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.9%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio is presently 91.49%.

Analyst Ratings Changes

PFE has been the subject of a number of analyst reports. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Cantor Fitzgerald initiated coverage on Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. Leerink Partners cut their price objective on Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. BMO Capital Markets cut their price objective on Pfizer from $36.00 to $30.00 in a research note on Thursday, April 17th. Finally, TD Cowen dropped their price target on Pfizer from $32.00 to $28.00 and set a "hold" rating for the company in a research report on Tuesday, April 22nd. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $28.12.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.